Literature DB >> 7918305

Lp(a) concentration and apo(a) isoform size. Relation to the presence of coronary artery disease in familial hypercholesterolemia.

J F Bowden1, P H Pritchard, J S Hill, J J Frohlich.   

Abstract

We studied the relation between the concentration of lipoprotein(a) [Lp(a)] in plasma, apolipoprotein (a) [apo(a)] phenotype, and the clinical expression of coronary artery disease (CAD) in a previously described cohort of patients with familial hypercholesterolemia (FH) and an appropriate population of control subjects. The plasma concentration of Lp(a) was markedly skewed in both the FH and control populations; however, the distribution was less skewed in FH (50% greater than 300 mg/L) compared with control subjects (27% greater than 300 mg/L). Patients with FH had significantly higher median and mean log Lp(a) levels compared with control subjects. There was no difference in the level of Lp(a) between men and women in both the control and FH groups. Frequency distribution analysis of the major apo(a) isoform size for each subject showed that, in contrast to the near-normal distribution seen in control subjects, two major subpopulations were apparent in the FH cohort, based on apo(a) isoform size > 700 kD or < or = 700 kD. There was no correlation between Lp(a) plasma concentration and apo(a) isoform size in either population. FH subjects with smaller apo(a) isoforms were more likely to have a history of signs of, or symptoms of CAD than those with larger isoforms. These data illustrate that on the basis of Lp(a) plasma concentration alone, there is no significant difference between FH patients with and without signs or symptoms of CAD. In the control population the smaller apo(a) isoforms were associated with higher Lp(a) levels, whereas in the FH population both small and large apo(a) isoforms were associated with higher Lp(a) levels.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7918305     DOI: 10.1161/01.atv.14.10.1561

Source DB:  PubMed          Journal:  Arterioscler Thromb        ISSN: 1049-8834


  7 in total

Review 1.  Lipoprotein(a): an elusive cardiovascular risk factor.

Authors:  Lars Berglund; Rajasekhar Ramakrishnan
Journal:  Arterioscler Thromb Vasc Biol       Date:  2004-09-02       Impact factor: 8.311

2.  What is the role of lipoprotein abnormalities and platelet aggregation defects in cardiovascular disease in chronic dialysis patients?

Authors:  J Winkler; G Boner; D Gavish; J Fuchs; I Weinberger
Journal:  Int Urol Nephrol       Date:  1997       Impact factor: 2.370

Review 3.  Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology.

Authors:  Børge G Nordestgaard; Anne Langsted
Journal:  J Lipid Res       Date:  2016-09-27       Impact factor: 5.922

4.  Relation of Apo(a) size to carotid atherosclerosis in an elderly multiethnic population.

Authors:  Furcy Paultre; Catherine H Tuck; Bernadette Boden-Albala; Douglas E Kargman; Elizabeth Todd; Jeffrey Jones; Myunghee C Paik; Ralph L Sacco; Lars Berglund
Journal:  Arterioscler Thromb Vasc Biol       Date:  2002-01       Impact factor: 8.311

5.  Sib-pair analysis detects elevated Lp(a) levels and large variation of Lp(a) concentration in subjects with familial defective ApoB.

Authors:  Y Y van der Hoek; A Lingenhel; H G Kraft; J C Defesche; J J Kastelein; G Utermann
Journal:  J Clin Invest       Date:  1997-05-01       Impact factor: 14.808

6.  PCSK9 loss-of-function variants and Lp(a) phenotypes among black US adults.

Authors:  Matthew T Mefford; Santica M Marcovina; Vera Bittner; Mary Cushman; Todd M Brown; Michael E Farkouh; Sotirios Tsimikas; Keri L Monda; J Antonio G López; Paul Muntner; Robert S Rosenson
Journal:  J Lipid Res       Date:  2019-09-11       Impact factor: 5.922

7.  Hyperlipoproteinaemia(a) is a common cause of autosomal dominant hypercholesterolaemia.

Authors:  E Meriño-Ibarra; J Puzo; E Jarauta; A Cenarro; D Recalde; A L García-Otín; E Ros; E Martorell; X Pintó; M Franco; D Zambón; A Brea; M Pocoví; F Civeira
Journal:  J Inherit Metab Dis       Date:  2007-10-20       Impact factor: 4.982

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.